The Latest Cardiac and Vascular News
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that Dr. Jeffrey Carpenter’s submission “Refinement of the IFU for the Nellix® System for Endovascular Aneurysm Sealing Based Upon Outcomes From the EVAS FORWARD IDE Trial” has been accepted for a plenary […]
Endologix Enters into $170 Million Credit Facility with Deerfield Management IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it has entered into an agreement with Deerfield Management (“Deerfield”), a leading healthcare investment organization, to provide Endologix with up to $170 […]
Mar 31, 2017 – IRVINE, Calif.–(BUSINESS WIRE)– Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that the first patients were treated in the Expanding Patient Applicability with Polymer Sealing Ovation Alto Stent Graft (ELEVATE) IDE clinical study, the Company’s pivotal clinical trial to […]
